Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy—Third Edition

Dear Colleagues,

We are happy to launch the third installment in the Special Issue series "Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy”, following the success of the first (https://www.mdpi.com/journal/cancers/special_issues/PTMDT) and second (https://www.mdpi.com/journal/cancers/special_issues/D866VYVP2P) editions.

Pituitary tumors present a variety of hormonal activities and clinical features, some overt and others subtle. Functioning pituitary tumors are defined based on the autonomous/dysregulated secretion of pituitary hormones. In this Special Issue, we will explore recent molecular insights and advances in diagnosis and targeted therapy in pituitary tumors. For example, Cushing’s disease is defined by the autonomous secretion of ACTH and excess cortisol production, which are clearly manifested in the disease’s clinical features. Mutations in the ubiquitin-specific protease (USP) 8 or USP48 genes have been detected in Cushing’s disease. Hormones produced from pituitary tumors sometimes induce severe complications such as hypertension, hyperglycemia, osteoporosis, infections, atherosclerosis, and mental health disorders. The pathophysiological characteristics of hormone production and pituitary adenoma cells remain to be elucidated. In addition, the usefulness and accuracy of recent diagnostic criteria for pituitary tumors also need to be evaluated. The primary treatment for some types of pituitary tumors is the surgical excision of the adenoma from the pituitary; however, curative surgery is still challenging, and additional therapies are required to treat the resulting hypersecretion of hormones and tumor growth. This Special Issue will include original basic/translational/clinical research articles and reviews on aspects related to the pathophysiology, diagnosis, and potential treatment of pituitary tumors.

In recognition of your contributions to this field, we invite you and your group to submit a review or original research article to this Special Issue. The submission period will close on 31 October 2026. For submission information, please consult the Cancers website below and submit your manuscript via the online submission form, making reference to the Special Issue “Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy—Third Edition”.

We look forward to receiving your contributions.

Sincerely,
Dr. Kazunori Kageyama
Dr. Mitsuru Nishiyama
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.